Trials / Completed
CompletedNCT01908075
Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
REACH Fostair vs Seretide - Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 194,723 (actual)
- Sponsor
- Research in Real-Life Ltd · Network
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.
Detailed description
To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide®) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched. To evaluate respiratory outcomes for Fostair in comparison to Seretide using a UK primary care database (in patients switched for cost rather than clinical reasons).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FP/SAL | |
| DRUG | BDP/FOR |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2013-07-25
- Last updated
- 2013-07-25
Source: ClinicalTrials.gov record NCT01908075. Inclusion in this directory is not an endorsement.